Annovis Bio, Inc.
ANVS
Rank in Stocks
#23812
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Share Price
$0.9013
Last synced: 2026-11-09
Market Cap
$38.47M
Change (1 day)
6.68%
Change (1 year)
-62.91%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Annovis Bio, Inc. (ANVS)
Category
Healthcare
EPS for Annovis Bio, Inc. (ANVS)
EPS as of June 2026 TTM: $-1.79
According to Annovis Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-1.79. At the end of 2025 the company had an EPS of $-1.40, an increase over its 2024 EPS of $-2.02.
EPS history for Annovis Bio, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.79 | 27.86% |
| 2025 | $-1.40 | -30.69% |
| 2024 | $-2.02 | -67.58% |
| 2023 | $-6.23 | 100.97% |
| 2022 | $-3.10 | 63.16% |
| 2021 | $-1.90 | 118.39% |
| 2020 | $-0.87 | 521.43% |
| 2019 | $-0.14 | 40.00% |
| 2018 | $-0.10 | 0.00% |
| 2017 | $-0.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -974.86% |
US
|
|
| $-7.07 | 294.97% |
US
|
|
| $-5.29 | 195.53% |
AU
|
|
| $12.88 | -819.56% |
BE
|
|
| $21.56 | -1,304.47% |
NL
|
Questions about Annovis Bio, Inc.'s earnings per share (EPS)
What is Annovis Bio, Inc.'s earnings per share (EPS)?
Annovis Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-1.79, as of Jun 2026.
What was Annovis Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Annovis Bio, Inc.'s earnings per share (EPS) was $-1.40, compared with $-2.02 in 2024.
How has Annovis Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Annovis Bio, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.87) and lowest in 2023 ($-6.23).
How does Annovis Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Annovis Bio, Inc.'s earnings per share (EPS) ($-1.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.